KR920018066A - 트랜스-Pt(IV)복합체 - Google Patents

트랜스-Pt(IV)복합체 Download PDF

Info

Publication number
KR920018066A
KR920018066A KR1019920003874A KR920003874A KR920018066A KR 920018066 A KR920018066 A KR 920018066A KR 1019920003874 A KR1019920003874 A KR 1019920003874A KR 920003874 A KR920003874 A KR 920003874A KR 920018066 A KR920018066 A KR 920018066A
Authority
KR
South Korea
Prior art keywords
compound
trans
formula
ptcl
hydroxyl
Prior art date
Application number
KR1019920003874A
Other languages
English (en)
Inventor
프랜시스 제임스 바르너드 크리스토퍼
Original Assignee
엘 에스 브루어
존슨 맛쎄이 퍼블릭 리미티드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엘 에스 브루어, 존슨 맛쎄이 퍼블릭 리미티드 캄파니 filed Critical 엘 에스 브루어
Publication of KR920018066A publication Critical patent/KR920018066A/ko

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0086Platinum compounds
    • C07F15/0093Platinum compounds without a metal-carbon linkage
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

내용 없음

Description

트랜스-Pt(Ⅳ)화합물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (14)

  1. 일반식 Ⅰ ;
    PtX2Y2L1L2
    (여기서, L1및 L2가 모두 NH3가 아닌 것을 조건으로 L1및 L2각각은 아민 리간드이고, X 및 Y 각각은 할로겐, 히드록실, 또는 카르복실레이트, 또는 Y2또는 X2및 Y2는 디카르복실레이트이며, 여기서 리간드인 L1및 L2는 플라티늄 원자상에서 산호 트랜스 배치 위치이다)인 것을 특징으로 하는 트랜스-Pt(Ⅳ)화합물.
  2. 제1항에 있어서, 식 Ⅰ중 X가 염소인 것을 특징으로 하는 화합물.
  3. 제1항 또는 제2항에 있어서, 식 Ⅰ중 Y가 염소 또는 히드록실인 것을 특징으로 하는 화합물.
  4. 제3항에 있어서, 식 Ⅰ중 Y가 히드록실인 것을 특징으로 하는 화합물.
  5. 제1항 내지 제4항중 어느 한 항에 있어서, 식 Ⅰ중 리간드 L1및/또는 L2가 1차 아민 R-NH2(여기서, R은 직쇄사슬알킬, 분지된 사슬알킬 또는 시클로알킬임)인 것을 특징으로 하는 화합물.
  6. 제5항에 있어서, 리간드 L1및/또는 L2가 1차 아민 R-NH2(여기서, R은 시클로알킬)인 것을 특징으로 하는 화합물.
  7. 제1항에 있어서, 트랜스-〔PtCl2(OH2)(NH3)(c-C5H9NH|2〕인 것을 특징으로 하는 화합물.
  8. 제1항에 있어서, 트랜스-〔PtCl2(OH2)(NH3)(c-C6H11NH|2〕인 것을 특징으로 하는 화합물.
  9. 제1항에 있어서, 트랜스-〔PtCl2(OH2)((NH3)2(CHNH2)〕인 것을 특징으로 하는 화합물.
  10. 제1항에 있어서, 트랜스-〔PtCl2(OH2)(NH3)((NH3)2CHNH|2〕인 것을 특징으로 하는 화합물.
  11. 제1항에 있어서, 트랜스-〔PtCl2(OCOCH3)(NH3)(c-C6H11NH2)〕인 것을 특징으로 하는 화합물.
  12. 약제학적으로 수용가능한 희석제 또는 담체와 혼합한 특허청구번위 제1항 내지 제12항중의 어느 한 항에서 정의한 트랜스-Pt(Ⅳ)화합물로 이루어지는 것을 특징으로 하는 약제학적 조성물.
  13. 제12항에 있어서, 단위 투약 형태인 것을 특징으로 하는 조성물.
  14. 식 Ⅱ ;
    트랜스-〔PtX2L1L2
    (여기서, L1및 L2는 특허청구 범위 제1항에서 정의한 바와 같고, X는 할로겐 원자이다)의 트랜스-Pt(Ⅱ)화합물을 원하는 Y기원과 반응시키고, X2가 (OH)2이면 할로겐 원자를 히드록실로 교체하고, Y 또는 X 및 Y가 카르복실레이트이며, Y2및 Y2를 (OH)2로 가지는 대응화합물을 아실화시키는 것을 이루어진 것을 특징으로 하는 특허청구 점위 제1항에서 정의한 식 Ⅰ의 화합물을 제조하는 방법.
    ※참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920003874A 1991-03-09 1992-03-09 트랜스-Pt(IV)복합체 KR920018066A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919105037A GB9105037D0 (en) 1991-03-09 1991-03-09 Improvements in chemical compounds
GB91/05037.7 1991-03-09

Publications (1)

Publication Number Publication Date
KR920018066A true KR920018066A (ko) 1992-10-21

Family

ID=10691311

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920003874A KR920018066A (ko) 1991-03-09 1992-03-09 트랜스-Pt(IV)복합체

Country Status (14)

Country Link
US (1) US5194645A (ko)
EP (1) EP0503830A1 (ko)
JP (1) JPH04327596A (ko)
KR (1) KR920018066A (ko)
AU (1) AU641850B2 (ko)
CA (1) CA2061759A1 (ko)
FI (1) FI921021A (ko)
GB (1) GB9105037D0 (ko)
HU (2) HUT60747A (ko)
IE (1) IE920725A1 (ko)
IL (1) IL101068A0 (ko)
NO (1) NO920894L (ko)
NZ (1) NZ241768A (ko)
ZA (1) ZA921737B (ko)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857432A (en) * 1987-05-18 1989-08-15 Canon Kabushiki Kaisha Toner for developing electrostatic charge image
US5624919A (en) * 1993-09-14 1997-04-29 The University Of Vermont And State Agricultural College Trans platinum (IV) complexes
IT1273391B (it) * 1994-03-31 1997-07-08 Boehringer Mannheim Italia Platino complessi cationici trinucleari ad attivita' antitumorale e composizioni farmaceutiche che li contengono
GB9502799D0 (en) * 1995-02-14 1995-04-05 Johnson Matthey Plc Improvements in platinum complexes
WO1996026949A1 (fr) * 1995-02-28 1996-09-06 Debiopharm Sa Nouveaux complexes de platine (iv), leur procede de production et agents cancerostatiques les contenant
CZ288912B6 (cs) * 1998-05-27 2001-09-12 Lachema, A. S. Komplex platiny v oxidačním čísle IV, způsob přípravy tohoto komplexu, tento komplex jako léčivo a farmaceutická kompozice tento komplex obsahující
CZ288406B6 (en) * 1998-05-27 2001-06-13 Lachema Np Platinum complex of oxidation number II, process for preparing such complex, the complex functioning as medicament and pharmaceutical composition in which the complex is comprised
ES2160466B1 (es) * 1998-12-23 2002-06-16 Univ Madrid Autonoma Trans-(ptcl2(n,n-dimetilamina)(isopropilamina)).
IL145671A0 (en) 1999-04-13 2002-06-30 Anormed Inc Process for preparing amine platinum complexes
US6413953B1 (en) * 1999-04-13 2002-07-02 Anormed Inc. Pt(IV) antitumor agent
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
AUPQ641100A0 (en) * 2000-03-23 2000-04-15 Australia Nuclear Science & Technology Organisation Methods of synthesis and use of radiolabelled platinum chemotherapeutic ag ents
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
US6894049B1 (en) 2000-10-04 2005-05-17 Anormed, Inc. Platinum complexes as antitumor agents
ES2181602B1 (es) * 2001-07-30 2004-06-16 Universidad Autonoma De Madrid "complejo de pt(iv) con actividad antineoplasica: trans-(ptcl2 (oh)2( dimetilamina) (isopropilamina)) aplicable como antitumoral.
ES2214138B1 (es) * 2003-02-21 2005-10-16 Universidad Autonoma De Madrid Compuestos trans de platino (iv) de formula trans, trans, trans - (ptcl2 (oh)2 (amina) (dimetilamina)) con actividad antitumoral.
CN1296377C (zh) * 2003-06-11 2007-01-24 南京大学 含醚键羧酸根为配体的铂(ⅱ)配合物的制备
CZ296459B6 (cs) * 2004-09-14 2006-03-15 Pliva-Lachema A. S. Perorální farmaceutická kompozice pro cílený transport komplexu platiny do kolorektální oblasti, zpusob její prípravy a tato kompozice pro pouzití jako lécivo
WO2007006019A1 (en) * 2005-07-06 2007-01-11 University Of South Florida Materials and methods for screening, diagnosis and prognosis of conditions associated with stat protein expression
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
WO2009011861A1 (en) * 2007-07-16 2009-01-22 Poniard Pharmaceuticals, Inc. Oral formulations for picoplatin
WO2009099634A2 (en) * 2008-02-08 2009-08-13 Poniard Pharmaceuticals, Inc. Picoplatin and amrubicin to treat lung cancer
EP2404925A1 (en) 2010-07-09 2012-01-11 Universidad Autónoma de Madrid New all trans platinum (IV) complexes, their preparation and their use as antitumor agents

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4329299A (en) * 1979-08-23 1982-05-11 Johnson, Matthey & Co., Limited Composition of matter containing platinum
IL63658A0 (en) * 1980-09-03 1981-11-30 Johnson Matthey Plc Co-ordination compound of platinum and its preparation
FI861110A0 (fi) * 1986-03-17 1986-03-17 Kautar Oy Foerfarande foer framstaellning av en haerdad stenmaterialprodukt, isynnerhet betong.
DE68918878T2 (de) * 1988-02-02 1995-02-23 Johnson Matthey Inc Pt(IV) Komplexe.
GB8806044D0 (en) * 1988-03-14 1988-04-13 Johnson Matthey Plc Platinum coordination compounds
FI905018A0 (fi) * 1989-10-17 1990-10-12 Bristol Myers Squibb Co I vatten och loesningsmedel loesliga axiala hydroxi-och mono- och dikarboxylsyraderivat med stor tumoeraktivitet.

Also Published As

Publication number Publication date
US5194645A (en) 1993-03-16
ZA921737B (en) 1992-11-25
GB9105037D0 (en) 1991-04-24
CA2061759A1 (en) 1992-09-10
IL101068A0 (en) 1992-11-15
EP0503830A1 (en) 1992-09-16
AU641850B2 (en) 1993-09-30
HU9200793D0 (en) 1992-05-28
HUT60747A (en) 1992-10-28
NZ241768A (en) 1993-10-26
NO920894D0 (no) 1992-03-06
JPH04327596A (ja) 1992-11-17
HU210070A9 (en) 1995-02-28
NO920894L (no) 1992-09-10
FI921021A (fi) 1992-09-10
FI921021A0 (fi) 1992-03-09
AU1141992A (en) 1992-09-10
IE920725A1 (en) 1992-09-09

Similar Documents

Publication Publication Date Title
KR920018066A (ko) 트랜스-Pt(IV)복합체
KR960704919A (ko) 신규인 펩티드 유도체 (novel peptide derivative)
KR890013044A (ko) Pt(IV)착화합물
IL110577A (en) Pharmaceutical compositions comprising stabilized solutions of carboplatin or a malonato congener of platinum II antitumor agents
KR880007552A (ko) 암민-지환식아민-백금 착화합물 및 항 종양제
ES8604985A1 (es) Un procedimiento para producir un complejo de platino-diamino
KR920021141A (ko) 갈륨 화합물
KR900004714A (ko) 신규의 3,4-디아미노 퀴놀린 및 피리딘계 화합물
DE59310096D1 (de) Chelatkomplexe und Verfahren zu ihrer Herstellung
GB8810173D0 (en) Pharmaceutical compositions with anti-cancer activity & method for treatment of cancer
KR890014107A (ko) 백금 화학 요법약제
NO963926L (no) Trinukleære kationiske platinakomplekser med antitumoraktivitet og farmasöytiske sammensetninger inneholdende dem
KR890014570A (ko) 백금 배위화합물
ES421430A1 (es) Procedimiento para producir derivados carbostirilo.
ES337254A1 (es) Procedimiento para la preparacion de composiciones para combatir las algas.
KR900003177A (ko) 테트라시클릭계 우울증 치료제
KR890000507A (ko) 시스플라틴(cisplatin) 유사체 및 그의 합성
GB1184534A (en) Platinum Complexes of Organo Amino Phosphines
KR960706467A (ko) 아릴 할라이드 치환된 금속 착물, 이를 함유하는 약제, 진단상의 그의 용도 및 이 착물 및 약제의 제조 방법(Aryl Halide Substituted Metallic Complexes, Pharmaceuticals Containing These Complexes, Their Use for Diagnostic Purposes, and Methods for Preparing the Complexes and Pharmaceuticals)
KR900003174A (ko) 벤조푸로[3,2-c] 퀴놀린 화합물
GB1378127A (en) Scopolamine derivatives
DK0390138T3 (da) Platinkomplekser og antitumormidler med indhold deraf som aktiv bestanddel
ATE91033T1 (de) Photochromische zusammensetzung und diese zusammensetzung enthaltende gegenstaende.
US4835182B1 (ko)
KR910016673A (ko) 히드록시페닐프로피오네이트의 제조방법

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid